Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 15/20 | 0.63 |
| ▸ | UCHL1 | P09936 | 14/20 | 0.63 |
| ▸ | CTSB | P07858 | 6/20 | 0.63 |
| ▸ | CTSK | P43235 | 6/20 | 0.63 |
| ▸ | CTSS | P25774 | 5/20 | 0.63 |
| ▸ | CTSC | P53634 | 4/20 | 0.63 |
| ▸ | CTSL | P07711 | 4/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3808366 | 0.88 | CTSB (0.70) | USP30UCHL1CTSBCTSKCTSS | |
| SCHEMBL3808364 | 0.88 | CTSB (0.70) | USP30UCHL1CTSBCTSKCTSS | |
| SCHEMBL3810915 | 0.81 | USP30 (0.67) | USP30UCHL1CTSBCTSKCTSS | |
| SCHEMBL3810767 | 0.81 | USP30 (0.67) | USP30UCHL1CTSBCTSKCTSS | |
| SCHEMBL3808664 | 0.80 | USP30 (0.57) | USP30UCHL1CTSBCTSKCTSS | |
| SCHEMBL3806508 | 0.79 | CTSB (0.74) | USP30UCHL1CTSBCTSKCTSS | |
| SCHEMBL3806505 | 0.79 | CTSB (0.74) | USP30UCHL1CTSBCTSKCTSS | |
| SCHEMBL3808376 | 0.79 | USP30 (0.56) | USP30UCHL1CTSBCTSKCTSS | |
| SCHEMBL6859742 | 0.78 | UCHL1 (0.93) | USP30UCHL1CTSBCTSKCTSS | |
| SCHEMBL6856730 | 0.78 | USP30 (1.00) | USP30UCHL1CTSBCTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264499-A1 | Cathepsin C Inhibitors | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | US | claimed |
| WO-2009129371-A1 | CATHEPSIN C INHIBITORS | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | WO | claimed |
| US-20090264499-A1 | Cathepsin C Inhibitors | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | US | disclosed |
| WO-2009129371-A1 | CATHEPSIN C INHIBITORS | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | WO | disclosed |
| US-20090264499-A1 | Cathepsin C Inhibitors | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | US | disclosed |
| US-20090264499-A1 | Cathepsin C Inhibitors | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264499-A1 | Cathepsin C Inhibitors | CTSB, CTSF, CTSG | USP30 1138/4885UCHL1 159/4885CTSB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.